

33. (New) A transformant expressively carrying the vector of claim 29.
34. (New) An oligonucleotide comprising the nucleotide sequence of claim 28 (a) or a nucleotide sequence complementary to the complementary strand thereof, wherein said oligonucleotide comprises 15 nucleotides or more.
35. (New) An antisense polynucleotide against the polynucleotide of claim 28, or a portion thereof.
- B1
Cured*
-

REMARKS

Status of the claims

By this amendment, claims 2-5, 8, 11, 13-15, and 18 are canceled and claims 24-35 are added. Upon entry of this amendment, claims 24-35 will be pending.

Support for new claims

Support for new claims 24-35 is found throughout the specification and in canceled claims 2-5, 8, 11, 13-5, and 18. No new matter has been added.

Receipt of an initial Office Action on the merits is awaited.

If there are any questions concerning this application, the Examiner is courteously invited to contact the undersigned counsel.

Respectfully submitted,

Date Jan 21, 2003

By Stephen B. Maebius

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5300
Facsimile: (202) 672-5399

Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No. 19-0741 for any such fees; and applicant(s) hereby petition for any needed extension of time.